DPW Holdings Inc
Change company Symbol lookup
Select an option...
DPW DPW Holdings Inc
IWN iShares Russell 2000 Value ETF
XNXCX Nuveen California Select Tax-Free Income Portfolio
AMGN Amgen Inc
AMSC American Superconductor Corp
CVBF CVB Financial Corp
PHG Koninklijke Philips NV
IVR Invesco Mortgage Capital Inc
CORE Core-Mark Holding Company Inc
ATMH All Things Mobile Analytic Inc
Go

Company profile

DPW Holdings, Inc., formerly Digital Power Corporation, is engaged in the design, manufacture and sale of power system solutions for the applications in the medical, military, telecom and industrial markets. The Company operates through two segments: North America (sales through DPC) and Europe (sales through DPL). It offers a range of product variety, including custom product design, standard and modified-standard products. Its switching power rectifiers include defense and commercial custom power products, server power supplies, front-end, open-frame, enclosed, CompactPCI, MicroTCA, Desktop/Wall-mount Adaptors, Power over Ethernet (POE) and other product solutions. Its product power range is from 10 watts to 75,000 watts. The Company's subsidiary, DPL, operates under the brand name of Gresham Power Electronics (Gresham). DPL designs, manufactures and sells power products and system solutions for the European marketplace.

Closing Price
$5.23
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
1,939

10-day average volume:
12,878,765
1,939

BIIB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of January 12, 2021 in the Class Action Filed on Behalf of Biogen Inc. Limited Shareholders

7:26 pm ET November 20, 2020 (Newsfile) Print

New York, New York--(Newsfile Corp. - November 20, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Biogen Inc. (NASDAQ: BIIB) alleging that the Company violated federal securities laws.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7092/68689_428754_logo.jpg

Class Period: October 22, 2019 and November 6, 2019

Lead Plaintiff Deadline: January 12, 2021

Learn more about your recoverable losses in BIIB:

http://www.kleinstocklaw.com/pslra-1/biogen-inc-loss-submission-form?id=11121&from=5

The filed complaint alleges that Biogen Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the larger dataset did not provide necessary data regarding aducanumab's effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding the effectiveness of aducanumab, Biogen's investigational human monoclonal antibody studied for the treatment of early Alzheimer's disease; (3) the PRIME study did not and would not provide necessary data regarding aducanumab's effectiveness; (4) the data provided by the Company to the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Shareholders have until January 12, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

For additional information about the BIIB lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click the link above.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.

Empire State Building

350 Fifth Avenue

59th Floor

New York, NY 10118

jk@kleinstocklaw.com

Telephone: (212) 616-4899

Fax: (347) 558-9665

www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/68689

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.